Therapeutic agents such as tyrosine kinase inhibitors can target lung cancers, carrying EGFR mutations, but further studies are needed to assess the degree of possible cross-resistance with radiotherapy [reviewed in (47)]. Here, EGFR is linked to lung carcinoma.